Cenicriviroc 150 mg

DRUG2 trials

Sponsors

Tobira Therapeutics, Inc.

Conditions

Non-alcoholic Fatty Liver DiseasePrediabetic StatePrimary Sclerosing CholangitisType 2 Diabetes Mellitus

Phase 2

ORION: Effects of Cenicriviroc on Insulin Sensitivity in Subjects With Prediabetes or Type 2 Diabetes Mellitus (T2DM) and Suspected NAFLD

CompletedNCT02330549

Tobira Therapeutics, Inc.Non-alcoholic Fatty Liver Disease, Prediabetic State, Type 2 Diabetes Mellitus

Start: 2015-07-17End: 2016-09-08Updated: 2019-10-11

PERSEUS: Preliminary Efficacy and Safety of Cenicriviroc in Adult Participants With Primary Sclerosing Cholangitis

CompletedNCT02653625

Tobira Therapeutics, Inc.Primary Sclerosing Cholangitis

Start: 2016-03-14End: 2017-08-31Updated: 2018-10-01

Related Papers

Efficacy and Safety of Cenicriviroc in Patients With Primary Sclerosing Cholangitis: PERSEUS Study

Hepatology Communications2020-12-2251 citations